Press Room

PhRMApedia Press Room

PhRMApedia's Press Room will provide the most recent press releases. Search PhRMApedia for additional press releases.  PhRMApedia is your new resource hub. You can search our entire database of media releases, reports, white papers, videos and more. Type your keywords in the search bar and explore PhRMA’s resources. Search results will appear by type, title and date.

Washington, D.C. (July 15, 2015) – Pharmaceutical Research and Manufacturers of America (PhRMA) Vice President of Science and Regulatory Advocacy Sascha Haverfield, Ph.D., and Biotechnology Industry Organization (BIO) Senior Vice President of Science Policy Kay Holcombe released the following joint statement on the reauthorization of the Prescription Drug User Fee Act (PDUFA):

“For more than 20 years, PDUFA has helped the Food and Drug Administration (FDA) fulfill its central mission of protecting and promoting public health by allowing the Agency to keep pace with the rapid increase in the number and complexity of innovative drugs and biologics requiring regulatory review.

Read More

Since 1998, 123 Alzheimer’s medicines failed in clinical trials, but biopharmaceutical research companies committed to solving Alzheimer’s puzzle  

Live webcast to discuss report findings July 15 at 1:30 p.m. EDT at www.phrma.org/Alz15; join Twitter conversation with #Alz15 

Read More

Washington, D.C. (July 13, 2015) — America’s biopharmaceutical research companies are currently developing 420 medicines for patients suffering from neurological disorders, including epilepsy, Alzheimer’s disease, multiple sclerosis (MS) and Parkinson’s disease. As highlighted in a new report from the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Epilepsy Foundation, scientists around the globe are collaborating to find new or more effective treatments for patients with these complex disorders that attack the nervous system.

Read More

Washington, D.C. (July 10, 2015) — Pharmaceutical Research and Manufacturers of America (PhRMA) president and chief executive officer John J. Castellani issued the following statement on passage of the 21st Century Cures Act (H.R. 6) by the U.S. House of Representatives:

"PhRMA applauds the House of Representatives for the overwhelming passage of the 21st Century Cures Act and looks forward to continuing our work with the Senate to ensure biomedical advances continue and are available to the patients who need them to live longer, healthier lives.

Read More

WASHINGTON (July 7, 2015) — Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation announced the promotion of Eileen Cannon to president of its Foundation.

“On behalf of our member companies and staff, I’d like to congratulate Eileen on her well-deserved promotion to president of the PhRMA Foundation,” said John J. Castellani, president and chief executive officer, PhRMA. “Over the past 15 years, Eileen’s leadership has been instrumental in helping to connect promising young researchers to resources that not only help launch their careers, but also help to advance critical new science that contributes to the drug discovery process for patients.”

Read More

Washington, D.C. (June 22, 2015) — Pharmaceutical Research and Manufacturers of America (PhRMA) executive vice president, policy and research, Lori Reilly provided the following statement on the American Society of Clinical Oncology's (ASCO) conceptual framework for assessing the value of new cancer treatment options based on clinical benefit, side effects, and cost:

Read More

Werner Baumann, Chairman of the Board of Management, Bayer HealthCare AG

Giovanni Caforio, M.D., Chief Executive Officer, Bristol-Myers Squibb Company

Peter Greenleaf, Chief Executive Officer, Sucampo Pharmaceuticals, Inc.

Ramona Sequeira, President, Takeda Pharmaceuticals U.S.A., Inc.

Timothy P. Walbert, Chairman, President & Chief Executive Officer, Horizon Pharma plc

WASHINGTON (June 16, 2015) –– The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced the election of five of its newest members to its Board of Directors.

Read More

Washington, D.C. (June 11, 2015) Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Robert Zirkelbach issued the following statement:

The Pharmaceutical Research and Manufacturers of America (PhRMA) announced its opposition to H.R. 9, the Innovation Act, which was marked up and reported by the House Judiciary Committee earlier today. 

Read More

A supportive policy environment is what makes the difference to investors, say local executives of multinational companies

WASHINGTON, D.C. (June 11, 2015) – In a new study from Pugatch Consilium consultancy, the U.S. and European economies continue to top the global charts in terms of attractiveness for biopharmaceutical investment. Notwithstanding low costs and considerable potential, emerging markets still come in at the bottom. Canada is also found to be surprisingly low on the list compared to developed economies, mainly due to challenging intellectual property policies.

Read More

Washington, D.C. (May 21, 2015) — Pharmaceutical Research and Manufacturers of America (PhRMA) president and chief executive officer John J. Castellani issued the following statement on the House Energy and Commerce Committee’s passage of 21st Century Cures legislation:

Read More

WASHINGTON (May 15, 2015) – PhRMA President and Chief Executive Officer John J. Castellani announced today that Executive Vice President, Administration, and Chief Financial Officer Del Persinger will retire effective May 31, concluding 18-1/2 years leading the organization’s finance and operations functions. Paul A. Aines, currently Chief Financial Officer and Senior Director of the American Society of Clinical Oncology (ASCO), will succeed Persinger. Aines will start at PhRMA on June 15.

Read More

Data Released Today is Misleading

WASHINGTON, D.C. (April 30, 2015) – Pharmaceutical Research and Manufacturers of America (PhRMA) president and CEO John J. Castellani released the following statement on today’s Medicare Part D data release:

“PhRMA supports efforts to increase transparency in health care costs, which can help support improved health care quality and efficiency. However, the Medicare Part D cost data released today are misleading and an inaccurate representation of actual Medicare Part D spending.

Read More

WASHINGTON, D.C. (April 30, 2015) – Pharmaceutical Research and Manufacturers of America (PhRMA) Vice President Jay Taylor issued the following statement today:

America’s innovative biopharmaceutical manufacturers and the more than 810,000 women and men they employ depend on strong intellectual property protection and enforcement to bring new medicines to patients who need them. Today, more than 7,000 medicines are in development across the country and around the world.

Read More

WASHINGTON, D.C. (April 29, 2015) – Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Robert Zirkelbach issued the following statement:

“The Pharmaceutical Research and Manufacturers of America (PhRMA) appreciates the efforts of Senate Judiciary Committee Chairman Chuck Grassley (R-IA), Ranking Member Patrick Leahy (D-VT), Senator John Cornyn (R-TX), and Senator Chuck Schumer (D-NY) in introducing legislation today to address abusive patent litigation. While the Senate legislation is an improvement over the House version, there continue to be issues of concern that intellectual property holders have raised, and we look forward to working with Senators to address those concerns.

Read More

Washington, D.C. (April 29, 2015) — Pharmaceutical Research and Manufacturers of America (PhRMA) president and chief executive officer John J. Castellani issued the following statement on the newly released 21st Century Cures draft:

“PhRMA applauds the work of Chairman Upton, Congresswoman DeGette, Ranking Member Pallone and members of the Committee for their tireless work to issue the latest Cures draft after a year of working with stakeholders, patient groups and others to accelerate the discovery, development and delivery of new medicines for patients. We strongly supported the House Energy and Commerce Committee’s bipartisan effort to develop this draft and were pleased to provide feedback during the process.

Read More

Pages

More On PhRMA — powered by PhRMApedia

Most Read